Intellia Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
656
- Stock Symbol
-
NTLA
- Investments
-
4
- Share Price
-
$9.58
- (As of Tuesday Closing)
Intellia Therapeutics General Information
Description
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Contact Information
Website
www.intelliatx.comCorporate Office
- 40 Erie Street
- Cambridge, MA 02139
- United States
Corporate Office
- 40 Erie Street
- Cambridge, MA 02139
- United States
Intellia Therapeutics Stock Performance
As of 17-Jun-2025, Intellia Therapeutics’s stock price is $9.58. Its current market cap is $992M with 104M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.58 | $8.96 | $5.90 - $28.18 | $992M | 104M | 4.35M | -$5.23 |
Intellia Therapeutics Financials Summary
As of 31-Mar-2025, Intellia Therapeutics has a trailing 12-month revenue of $45.6M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 344,692 | 631,063 | 1,994,078 | 2,277,558 |
| Revenue | 45,569 | 57,877 | 36,275 | 52,121 |
| EBITDA | (559,421) | (556,528) | (522,024) | (475,128) |
| Net Income | (525,914) | (519,021) | (481,192) | (474,186) |
| Total Assets | 986,163 | 1,191,015 | 1,300,977 | 1,520,114 |
| Total Debt | 119,253 | 210,198 | 115,346 | 130,703 |
Intellia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Intellia Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Intellia Therapeutics Comparisons
Industry
Financing
Details
Intellia Therapeutics Competitors (48)
One of Intellia Therapeutics’s 48 competitors is Editas Medicine, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA |
Intellia Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Intellia Therapeutics Patents
Intellia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240417752-A1 | Systems, devices, and methods of a data pipeline | Pending | 13-Jun-2023 | ||
| AU-2023409139-A1 | Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing | Pending | 21-Dec-2022 | ||
| AU-2023304427-A1 | Methods for in vivo editing of klkb1 | Pending | 08-Jul-2022 | ||
| EP-4551701-A1 | Methods for in vivo editing of klkb1 | Pending | 08-Jul-2022 | ||
| AU-2023299294-A1 | Engineered t cells | Pending | 29-Jun-2022 | C12N5/0636 |
Intellia Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Intellia Therapeutics Investments & Acquisitions (4)
Intellia Therapeutics’s most recent deal was a Later Stage VC with Kyverna for . The deal was made on 06-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kyverna | 06-Nov-2023 | Later Stage VC | Biotechnology | ||
| Rewrite therapeutics | 02-Feb-2022 | Merger/Acquisition | Biotechnology | ||
| SparingVision | 13-Oct-2021 | Later Stage VC | Drug Discovery | ||
| AvenCell | 30-Jul-2021 | Joint Venture | Biotechnology |
Intellia Therapeutics ESG
Risk Overview
Risk Rating
Updated May, 23, 2025
28.16 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Intellia Therapeutics Exits (1)
Intellia Therapeutics’s most recent exit was on 06-Nov-2023 from Kyverna. The exit was categorized as with 15 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kyverna | 06-Nov-2023 | Completed |
|
Intellia Therapeutics FAQs
-
When was Intellia Therapeutics founded?
Intellia Therapeutics was founded in 2014.
-
Where is Intellia Therapeutics headquartered?
Intellia Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Intellia Therapeutics?
Intellia Therapeutics has 656 total employees.
-
What industry is Intellia Therapeutics in?
Intellia Therapeutics’s primary industry is Biotechnology.
-
Is Intellia Therapeutics a private or public company?
Intellia Therapeutics is a Public company.
-
What is Intellia Therapeutics’s stock symbol?
The ticker symbol for Intellia Therapeutics is NTLA.
-
What is the current stock price of Intellia Therapeutics?
As of 17-Jun-2025 the stock price of Intellia Therapeutics is $9.58.
-
What is the current market cap of Intellia Therapeutics?
The current market capitalization of Intellia Therapeutics is $992M.
-
What is Intellia Therapeutics’s current revenue?
The trailing twelve month revenue for Intellia Therapeutics is $45.6M.
-
Who are Intellia Therapeutics’s competitors?
Editas Medicine, Sangamo Therapeutics, Caribou Biosciences, CRISPR Therapeutics, and Allogene Therapeutics are some of the 48 competitors of Intellia Therapeutics.
-
What is Intellia Therapeutics’s annual earnings per share (EPS)?
Intellia Therapeutics’s EPS for 12 months was -$5.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
